Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Amortizatization of Intangibles (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Amortizatization of Intangibles data on record, last reported at $882000.0 in Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 73.77% year-over-year to $882000.0; the TTM value through Dec 2025 reached $5.9 million, down 62.82%, while the annual FY2025 figure was $5.9 million, 62.82% down from the prior year.
  • Amortizatization of Intangibles reached $882000.0 in Q4 2025 per CLDX's latest filing, down from $1.0 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $4.7 million in Q2 2024 and bottomed at -$772000.0 in Q1 2022.
  • Average Amortizatization of Intangibles over 5 years is $1.5 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Amortizatization of Intangibles: surged 3617.24% in 2021, then crashed 1708.33% in 2022.
  • A 5-year view of Amortizatization of Intangibles shows it stood at -$198000.0 in 2021, then soared by 363.64% to $522000.0 in 2022, then skyrocketed by 317.43% to $2.2 million in 2023, then surged by 54.34% to $3.4 million in 2024, then crashed by 73.77% to $882000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $882000.0 in Q4 2025, $1.0 million in Q3 2025, and $1.7 million in Q2 2025.